详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH.

29| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Clinical Medicine of “5+3” Program, Xuanwu Hospital, Capital Medical University, Beijing, China [2]Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China [3]Department of Oral Medicine, Basic Medical College, Capital Medical University, Beijing, China [4]Eight Program of Clinical Medicine, Peking University Health Science Center, Beijing, China [5]Department of Biomedical Informatics, School of Biomedical Engineering. Capital Medical University, Beijing, China [6]Morphological Experiment Center, School of Basic Medical Sciences, Capital Medical University, Beijing, China

出处：

DOI：

ISSN：

关键词： GLP-1 Alzheimer’s disease blood pressure DPP-4 non-alcoholic steatohepatitis signaling pathway

摘要：

GLP-1 is derived from intestinal L cells, which takes effect through binding to GLP-1R and is inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). Since its discovery, GLP-1 has emerged as an incretin hormone for its facilitation in insulin release and reduction of insulin resistance (IR). However, GLP-1 possesses broader pharmacological effects including anti-inflammation, neuro-protection, regulating blood pressure (BP), and reducing lipotoxicity. These effects are interconnected to the physiological and pathological processes of Alzheimer's disease (AD), hypertension, and non-alcoholic steatohepatitis (NASH). Currently, the underlying mechanism of these effects is still not fully illustrated and a better understanding of them may help identify promising therapeutic targets of AD, hypertension, and NASH. Therefore, we focus on the biological characteristics of GLP-1, render an overview of the mechanism of GLP-1 effects in diseases, and investigate the potential of GLP-1 analogues for the treatment of related diseases in this review.Copyright © 2021 Li, Gao, Guo, Wang, Hua, Gao, Shang, Lu and Xu.

基金：

基金编号： 8217140592,.81673671 2016YFC1306305J-DX

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 3 区医学

小类 | 3 区内分泌学与代谢

最新[2025]版：

大类 | 3 区医学

小类 | 3 区内分泌学与代谢

JCR分区：

出版当年[2019]版：

Q2 ENDOCRINOLOGY & METABOLISM

最新[2023]版：

Q2 ENDOCRINOLOGY & METABOLISM

影响因子： 3.9 最新[2023版] 4.9 最新五年平均 3.644 出版当年[2019版] 3.986 出版当年五年平均 3.634 出版前一年[2018版] 5.555 出版后一年[2020版]

第一作者：

第一作者机构： [1]Clinical Medicine of “5+3” Program, Xuanwu Hospital, Capital Medical University, Beijing, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH.

文献详情

相关文献